Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
about
Risperidone versus placebo for schizophreniaInvestigating Cortical Inhibition in First-Degree Relatives and Probands in SchizophreniaClinical utility of the risperidone formulations in the management of schizophrenia.Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsThe effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium.Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Almost all antipsychotics result in weight gain: a meta-analysis.Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.Evidence for inhibitory deficits in the prefrontal cortex in schizophrenia.Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort studyLong-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia.Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.Association between non-compliance with psychiatric treatment and non-psychiatric service utilization and costs in patients with schizophrenia and related disorders.Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysisCost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Improving social cognition in schizophrenia: a pilot intervention combining computerized social cognition training with cognitive remediation.Risperidone long-acting injection: safety and efficacy in elderly patients with schizophrenia.Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studiesImpact of risperidone long acting injection on resource utilization in psychiatric secondary care.A review of the association between antipsychotic use and hyperprolactinaemia.Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design featuresProgress in compliance research and intervention: a commentary.Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada.Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006).Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Explicit review of risperidone long-acting injection prescribing practice.Evaluating appropriateness of prescribing of long-acting risperidone for injection in acute care settings.Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.
P2860
Q24241041-6C595C99-5CAD-415A-822E-E0AC1F1DA7BFQ30358965-E748CAB6-C052-45DA-9D8F-F381F3B792F8Q30429721-42CE5689-D948-4FFB-B4FB-7DFE02EDDDD5Q30542486-127F521A-473B-40F6-B04D-BE0567A4B3DDQ31038656-7A3FB233-692C-473B-9473-54ABB50470F8Q33566124-48ACB4C6-BBFF-42EE-AD87-7B401ABF8390Q33619940-0E29DC9C-F7DF-4008-B8F5-C2A0FC0282A7Q33802918-F6307EAC-59F4-482A-A841-AC5914912CAAQ33862078-16310B99-3AB2-4A4A-848A-8E6875BB4FD1Q34048194-9EAF77B0-1E1B-4125-A038-44E28997BE14Q34315836-EFCA10F6-3C8E-458A-83F8-EB46D2138B2AQ34418847-31D80086-9091-453D-B1FD-ED2E3E20B653Q34661499-9B6052CB-E172-4EB4-8EF1-EAB9C207F962Q34775426-5F684FDF-9734-42B7-B1AC-1A664DD35C30Q35014889-309EA125-B83B-4A2A-8573-62AFE4D6F193Q35030003-E85FBC1F-2543-404B-B765-7494853F9795Q35143555-AB805CDC-FC01-42FF-AFDB-DEC2E7A5F6EAQ35971060-2D17662E-3B72-4AD7-9498-8268B680D1F1Q36144552-00C49741-B01E-47A9-BB49-0DB2294AC169Q36198389-E20350FA-6419-4AAC-ABD3-1BD8B8F06CF1Q36220825-DD8F7557-FCBE-4DE7-AEFF-6A14521A348FQ36550998-46C6C627-041B-4AEE-A1EB-4101D040B3B3Q36698856-C9343C1B-A666-400E-90BF-C41F8CB96747Q36770010-436DD729-4153-49F1-9B08-FA379D68EB04Q36873892-B3BF83F9-295F-4CF8-AA60-35BC51E40A88Q37042180-0077FA03-4853-44D3-BB0D-05AC145236D1Q37097631-5AEDF526-AB57-443F-AC85-A55695CE29FCQ37162798-08259AA2-AC60-4934-B0F5-41E8E42A8849Q37227479-6B2760F2-FAD0-458E-931B-4E2BE65C2153Q37236153-E8FC76BE-0EEB-4B42-B0B8-AFA5ACDE0BD1Q37356486-6C61E98E-CA50-44A0-9095-C22FC31073FBQ37418931-CE2E37C2-70AF-40C7-96E4-7F08F0C53DFCQ37616971-BC32D2E7-3D0C-4AC9-B8BB-C8F2CAAA8E49Q37763151-AB3CA444-2D0C-4D10-A455-0E7C034D4E5FQ37778398-6B6E91FF-176C-4519-95C4-E035534BEE05Q37948911-6428B231-E9DD-4A0E-9D0F-D7E8376A3EF6Q38000246-A0AC1302-37D7-42B7-9C61-05682EBFB269Q38042430-2F18569B-009A-4538-8DB7-BC58A3265ED7Q38115487-B2C4C23C-3878-4365-8E60-218B4359052AQ38125213-FE220078-2B36-4A6A-B83D-0F927F9B9D8B
P2860
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
@en
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
@nl
type
label
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
@en
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
@nl
prefLabel
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
@en
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
@nl
P2093
P1476
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
@en
P2093
Anthony S David
Bernard Lachaux
H Pretorius
Ilse Augustyns
Lars Eriksson
Marielle Eerdekens
Peter Molcan
Pierre Chue
P304
P356
10.1016/J.EURONEURO.2004.07.003
P407
P577
2005-01-01T00:00:00Z